Verteporfin
From Wikipedia, the free encyclopedia
 |
|
|
Verteporfin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C41H42N4O8 |
| Mol. mass | 718.794 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Verteporfin, otherwise known as benzoporphyrin derivative (trade name Visudyne), is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
[edit] Administration
Verteporfin is given intravenously, within 15 minutes before laser treatment.
[edit] Side effects
Most commonly, blurred vision. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
